Journey Medical Q2 net loss $8.4M, revenue $17.2M; DFD-29 Phase 3 positive, NDA submission H2 2023

Journey Medical Corp

2023-Q2 EPS reported -$1.03 revenue$29,385,000

Q2 2023 net revenues $17.2M, down 6% YoY but up 41% QoQ; core product revenue grew 19% YoY to $15.6M (92% of total).
GAAP net loss $8.4M ($0.46/sh) vs $7.5M loss ($0.43/sh) in Q2 2022; adjusted EBITDA improved to -$0.6M from -$2.6M.
DFD-29 Phase 3 trials met co-primary and all secondary endpoints, superior to placebo and Oracea; NDA submission planned H2 2023.
Non-cash impairment of Ximino intangible asset of $3.1M; SG&A down 20% to $12.1M from cost reduction initiatives.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Journey Medical Corp reported the second quarter ended June 30, 2023 results: revenue $17.2 million, net income GAAP net loss was $8.4 million, or $0.46 per share basic and diluted, EPS $0.46 per share basic and diluted.

Period: the second quarter ended June 30, 2023
Revenue: $17.2 million
Net income: GAAP net loss was $8.4 million, or $0.46 per share basic and diluted
EPS: $0.46 per share basic and diluted
Result: reported results

Exact text from the filing

EXHIBIT 99.1 Exhibit 99.1 Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights The Company generated total net revenues of $17.2 million in the second quarter of 2023, a 41% increase from $12.2 million in the first quarter of 2023 Announced positive topline results from two Phase 3 clinical trials evaluating

View on SEC.gov

Browse all earnings releases →

Journey Medical Corp filing history →

Source: SEC EDGAR

accession 0001104659-23-088823

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.